Eric Padron, MD, shares results from the phase I study of ruxolitinib in chronic myelomonocytic leukemia, a rare type of myelodysplastic, myeloproliferative neoplasm with few treatment options.
Ruxolitinib in CMML: Study Shows Promising Results
Recent Articles
pASHions: Mrinal Patnaik, MBBS
In this edition, Mrinal Patnaik, MBBS, explains his fascination with snakes and how venomous reptiles have contributed to hematology. Dr. Patnaik is associate professor...
Examining Ibrutinib as Secondline Therapy for Chronic Graft-Versus-Host Disease
On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved the Bruton tyrosine kinase inhibitor ibrutinib as a secondline treatment for adult...
Treating Spin Doctors
Recently, a hospital in Boston announced that a senior staff scientist had developed a “cure” for leukemia. I wasn’t surprised to read this –...
European Commission Approves Obinutuzumab Combination Treatment for FL
The European Commission approved obinutuzumab in combination with chemotherapy as firstline treatment for patients with previously untreated, advanced follicular lymphoma (FL), followed by obinutuzumab...
Maryland Enacts First Price-Gouging Law for Pharmaceutical Companies
By denying an injunction filed by a generic-drug industry trade group, a U.S. District Court allowed Maryland to implement the first law penalizing drug...
Current Issue
October 2017, Volume 3, Issue 12
This issue features a look at hospital ranking systems, the risks and benefits of opioids for pain management, and more.
